Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a favourable prognosis. However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect of the expression of different combinations of these receptors on patient survival is not well understood. Therefore, we examined the mRNA expression of all four EGF receptors with real-time polymerase chain reaction in biopsies from 88 patients with bladder cancer, where the survival was followed for a median of 38.5 months (range 1-117 months). Expression of HER1 and HER2 alone showed no correlation with survival. However, a high expression of HER1 together with high expression of HER3 and HER4 correlated to a better prognosis compared to the high expression of HER1 together with low expression of HER3 and HER4 (P=0.0006). Also, a significantly longer survival was observed in patients expressing high HER2 when coexpressed with high HER3 and HER4, as compared to the survival in patients with tumours expressing high HER2 but low HER3 and HER4 (P=0.0005). Our results suggest that the final outcome of patients with high HER1- and HER2-expressing tumours depends on the expression of HER3 and HER4.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361308 | PMC |
| http://dx.doi.org/10.1038/sj.bjc.6603154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptomic analysis of + non-small cell lung cancer reveals an upregulation of nucleotide synthesis and cell adhesion pathways.
Front Oncol
December 2024
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
Introduction: The transcriptomic characteristics of + non-small cell lung cancer (NSCLC) represent a crucial aspect of its tumor biology. These features provide valuable insights into key dysregulated pathways, potentially leading to the discovery of novel targetable alterations or biomarkers.
Methods: From The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, all available + (n = 10), + (n = 5) and + (n = 5) NSCLC tumor and + cell line (n = 7) RNA-sequencing files were collected.
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.
Oncol Rep
December 2024
Department of Biomolecular Sciences, School of Life Science, Pharmacy and Chemistry, Faculty of Health, Science, Social Care and Education, Kingston University London, Kingston upon Thames KT1 2EE, UK.
The aberrant expression of HER family members and cancer stem cells (CSCs) have been associated with tumour progression and resistance to therapy. At present, several HER inhibitors have been approved for the treatment of patients with a range of cancers but not for the treatment of patients with hepatocellular carcinoma (HCC). The present study investigated the co‑expression and prognostic significance of HER family members, type‑III deletion mutant EGFR (EGFRvIII), and the putative CSC biomarkers CD44 and epithelial cell adhesion molecule (EpCAM) in 43 patients with HCC.
View Article and Find Full Text PDFTargeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.
Front Pharmacol
August 2024
College of Medicine, QU Health, Qatar University, Doha, Qatar.
Article Synopsis
- The epidermal growth factor receptor (EGFR, also known as ErbB1/HER1) is a key receptor involved in kidney development and repair, but its prolonged activation can lead to various kidney diseases like diabetic nephropathy and chronic kidney disease.
- Recent research highlights the effects of EGFR activation on kidney health and suggests a possible protective role of the angiotensin-(1-7) peptide, which may inhibit EGFR’s harmful effects.
- The review proposes that EGFR inhibitors already used for cancer treatment, like Gefitinib and Erlotinib, could be repurposed to treat kidney-related issues due to their proven safety and effectiveness.
Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents.
Bioorg Chem
October 2024
School of Pharmacy, China Medical University, Shenyang 110122, PR China. Electronic address:
Article Synopsis
- * Compound 12k was identified as the most effective dual-target inhibitor, showing superior potency compared to the clinically used drug Lapatinib.
- * In both laboratory and animal models, compound 12k demonstrated strong anti-cancer activities with minimal side effects, successfully inhibiting the growth and migration of cancer cells while inducing cell death.
The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
Pharmaceutics
July 2024
Center for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Current therapies targeting the human epidermal growth factor receptor (HER) family, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), are limited by drug resistance and systemic toxicities. Antibody-drug conjugates (ADCs) are one of the most rapidly expanding classes of anti-cancer therapeutics with 13 presently approved by the FDA. Importantly, ADCs represent a promising therapeutic option with the potential to overcome traditional HER-targeted therapy resistance by delivering highly potent cytotoxins specifically to HER-overexpressing cancer cells and exerting both mAb- and payload-mediated antitumor efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!